• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Familial non-medullary thyroid cancer: a critical review.家族性非髓样甲状腺癌:批判性综述。
J Endocrinol Invest. 2021 May;44(5):943-950. doi: 10.1007/s40618-020-01435-x. Epub 2020 Oct 6.
2
[A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].[家族性非髓样甲状腺癌(FNMTC):临床与遗传学最新进展]
Rev Med Liege. 2016 Dec;71(12):557-561.
3
Familial non-medullary thyroid cancer: unraveling the genetic maze.家族性非髓样甲状腺癌:解开基因迷宫
Endocr Relat Cancer. 2016 Dec;23(12):R577-R595. doi: 10.1530/ERC-16-0067. Epub 2016 Nov 2.
4
Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.家族性非髓样甲状腺癌的大型单中心系列的临床和遗传特征。
Front Endocrinol (Lausanne). 2021 Jan 7;11:589340. doi: 10.3389/fendo.2020.589340. eCollection 2020.
5
FAMILIAL NON-MEDULLARY THYROID CARCINOMA.家族性非髓样甲状腺癌。
Exp Oncol. 2023 Jun 26;45(1):70-78. doi: 10.15407/exp-oncology.2023.01.070.
6
An update on familial nonmedullary thyroid cancer.家族性非髓样甲状腺癌的最新进展。
Endocrine. 2020 Jun;68(3):502-507. doi: 10.1007/s12020-020-02250-3. Epub 2020 Mar 11.
7
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.家族性与散发性非髓样甲状腺癌的患病率、临床病理特征和体细胞基因突变谱。
Thyroid. 2011 Apr;21(4):367-71. doi: 10.1089/thy.2010.0256. Epub 2010 Dec 29.
8
Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.新型易感性基因驱动大型近亲家族性非髓样甲状腺癌。
Int J Mol Sci. 2023 May 4;24(9):8233. doi: 10.3390/ijms24098233.
9
Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.全外显子组和靶向测序鉴定 MAP2K5 为家族性非髓样甲状腺癌的新易感基因。
Int J Cancer. 2019 Mar 15;144(6):1321-1330. doi: 10.1002/ijc.31825. Epub 2018 Sep 24.
10
Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.家族性非髓样甲状腺癌:临床病理特征、遗传风险因素的当前知识和新进展。
Minerva Endocrinol (Torino). 2021 Mar;46(1):5-20. doi: 10.23736/S2724-6507.20.03338-6. Epub 2020 Oct 12.

引用本文的文献

1
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.甲状腺癌:流行病学、分类、危险因素、诊断和预后标志物以及当前的治疗策略。
Int J Mol Sci. 2025 May 28;26(11):5173. doi: 10.3390/ijms26115173.
2
Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients.家族性非髓样甲状腺癌与散发性分化型甲状腺癌患者无进展生存期的比较
Thyroid. 2025 Jun;35(6):642-651. doi: 10.1089/thy.2024.0588. Epub 2025 May 20.
3
The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis.个性化医疗时代放射性碘治疗家族性非髓样甲状腺癌的疗效分析:一项队列研究和荟萃分析
Ann Nucl Med. 2025 Jun;39(6):535-545. doi: 10.1007/s12149-025-02029-4. Epub 2025 Feb 20.
4
Approach to the Pediatric Patient with Thyroid Nodules.小儿甲状腺结节患者的诊疗方法
J Clin Endocrinol Metab. 2025 Feb 13. doi: 10.1210/clinem/dgaf090.
5
Narrative overview of possible preventive measures for differentiated thyroid carcinomas.分化型甲状腺癌可能的预防措施概述
Heliyon. 2024 Dec 18;11(1):e41284. doi: 10.1016/j.heliyon.2024.e41284. eCollection 2025 Jan 15.
6
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.共识声明:甲状腺癌管理中可操作生物标志物检测的建议
Endocr Pathol. 2024 Dec;35(4):293-308. doi: 10.1007/s12022-024-09836-x. Epub 2024 Nov 23.
7
Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.端粒延长种系变异易患综合征型甲状腺乳头状癌亚型。
Am J Hum Genet. 2024 Jun 6;111(6):1114-1124. doi: 10.1016/j.ajhg.2024.04.006. Epub 2024 Apr 29.
8
Investigating Mutation as Underlying Cause of Familial Non-Medullary Thyroid Carcinoma.研究家族性非髓样甲状腺癌的潜在病因——突变。
Int J Mol Sci. 2024 Jan 26;25(3):1522. doi: 10.3390/ijms25031522.
9
MEN1 in a Patient With Nonsyndromic Familial Nonmedullary Thyroid Carcinoma.非综合征性家族性非髓样甲状腺癌患者的多发性内分泌腺瘤1型
JCEM Case Rep. 2022 Nov 30;1(1):luac019. doi: 10.1210/jcemcr/luac019. eCollection 2023 Jan.
10
Clinical relevance and outcome of familial papillary thyroid cancer: a single institution study of 626 familial cases.家族性甲状腺乳头状癌的临床意义和结局:一家机构 626 例家族性病例的研究。
Front Endocrinol (Lausanne). 2023 Sep 14;14:1200855. doi: 10.3389/fendo.2023.1200855. eCollection 2023.

本文引用的文献

1
Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma.家族性和散发性乳头状甲状腺癌的长期临床结局
Eur Thyroid J. 2020 Jul;9(4):213-220. doi: 10.1159/000506955. Epub 2020 Apr 28.
2
Leukocyte Telomere Length and Risk of Papillary Thyroid Carcinoma.白细胞端粒长度与甲状腺乳头状癌风险的关系。
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2712-2718. doi: 10.1210/jc.2018-02471.
3
Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.全外显子组和靶向测序鉴定 MAP2K5 为家族性非髓样甲状腺癌的新易感基因。
Int J Cancer. 2019 Mar 15;144(6):1321-1330. doi: 10.1002/ijc.31825. Epub 2018 Sep 24.
4
Genome-wide association study of familial lung cancer.家族性肺癌的全基因组关联研究。
Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.
5
Results of Screening in Familial Non-Medullary Thyroid Cancer.家族性非髓样甲状腺癌的筛查结果。
Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19.
6
Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement.甲状腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2017 May 9;317(18):1882-1887. doi: 10.1001/jama.2017.4011.
7
Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.透明质酸结合蛋白2(HABP2)的分离与表达分析:来自大量家族性非髓样甲状腺癌的见解及文献综述
Clin Endocrinol (Oxf). 2017 Jun;86(6):837-844. doi: 10.1111/cen.13316. Epub 2017 Mar 23.
8
Tumor characteristics and prognosis in familial breast cancer.家族性乳腺癌的肿瘤特征与预后
BMC Cancer. 2016 Nov 29;16(1):924. doi: 10.1186/s12885-016-2962-1.
9
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.家族性非髓样甲状腺癌中HABP2 G534E变异:一项意大利研究系列
J Endocrinol Invest. 2017 May;40(5):557-560. doi: 10.1007/s40618-016-0583-9. Epub 2016 Nov 21.
10
Familial non-medullary thyroid cancer: unraveling the genetic maze.家族性非髓样甲状腺癌:解开基因迷宫
Endocr Relat Cancer. 2016 Dec;23(12):R577-R595. doi: 10.1530/ERC-16-0067. Epub 2016 Nov 2.

家族性非髓样甲状腺癌:批判性综述。

Familial non-medullary thyroid cancer: a critical review.

机构信息

Section of Endocrinology and Metabolism, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100, Siena, Italy.

Institute of Endocrinology, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.

出版信息

J Endocrinol Invest. 2021 May;44(5):943-950. doi: 10.1007/s40618-020-01435-x. Epub 2020 Oct 6.

DOI:10.1007/s40618-020-01435-x
PMID:33025555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8049908/
Abstract

BACKGROUND

Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial form of the disease has also become more common than previously reported and constitutes nearly 10% of all thyroid cancers. Many aspects of FNMTC are debated, concerning both clinical and genetic aspects. Several studies reported that, in comparison with sporadic PTCs, FPTCs are more aggressive at disease presentation, while other authors reported no differences in the clinical behavior of sporadic and familial PTCs. For this reason, recent guidelines do not recommend screening of family members of patients with diagnosis of differentiated thyroid cancer (DTC). FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance. At the moment, the genetic factors contributing to the development of FNMTC remain poorly understood, though many putative genes have been proposed in the recent years.

PURPOSE

Based on current literature and our experience with FNMTC, in this review, we critically discussed the most relevant controversies, including its definition, the genetic background and some clinical aspects as screening and treatment.

摘要

背景

家族性非髓样甲状腺癌(FNMTC)主要为乳头状组织学类型(FPTC),其定义为在无其他已知家族综合征的情况下,两名或以上一级亲属患有该疾病。近年来,随着 PTC 发病率的增加,家族性疾病也变得比以前更为常见,约占所有甲状腺癌的 10%。FNMTC 的许多方面存在争议,包括临床和遗传方面。一些研究报告称,与散发性 PTC 相比,FPTC 在发病时侵袭性更强,而其他作者则报告称散发性和家族性 PTC 的临床行为无差异。因此,最近的指南不建议对诊断为分化型甲状腺癌(DTC)的患者的家庭成员进行筛查。FNMTC 被描述为一种与多个低至中度外显率易感基因和不完全外显率相关的多基因疾病。目前,导致 FNMTC 发生的遗传因素仍知之甚少,尽管近年来提出了许多假定基因。

目的

基于目前的文献和我们对 FNMTC 的经验,在这篇综述中,我们批判性地讨论了最相关的争议,包括其定义、遗传背景和一些临床方面,如筛查和治疗。